Hyperphosphatemia - The risk factor for adverse outcome in maintenance hemodialysis patients

Journal of Medical Biochemistry

Volumn 31, Issue 3, 2012, Pages 239-245

  Petrović, Dejan ^a   Obrenović, Radmila ^b   Trbojević Stanković, Jasna ^c   Majkić Singh, Nada ^b   Stojimirović, Biljana ^d  

^a CLINICAL CENTER KRAGUJEVAC   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c University Clinical Hospital Center Dr Dragisa Misovic Dedinje   (Serbia)

^d CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

cardiovascular mortality; hemodialysis; hyperphosphatemia

Indexed keywords

ALBUMIN; CALCIUM PHOSPHATE; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS; PROTEIN; UREA;

ADULT; ADVERSE OUTCOME; ALBUMIN BLOOD LEVEL; ARTERIAL PRESSURE; ARTICLE; CALCIFICATION; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CHRONIC PYELONEPHRITIS; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPHOSPHATEMIA; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE CALCIFICATION; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ULTRAFILTRATION; UREA BLOOD LEVEL; WEIGHT GAIN;

EID: 84861895512     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-012-0002-5     Document Type: Article

References (43)

1. Prie D, Urena P, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 2009; 75(9): 882-9.
2. Murer H, Hernando N, Forster I, Biber J. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 2000; 80(4): 1373-409.
3. Prie D, Beck L, Urena P, Friedlander G. Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens 2005; 14(4): 318-24. (Pubitemid 40863067)
4. Levin NW, Hoenich NA. Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Opin Nephrol Hypertens 2001; 10(5): 563-8. (Pubitemid 32783803)
5. Block GA, Port FK. Calcium Phosphate Metabolism and Cardiovascular Disease in Patients with Chronic Kidney Disease. Semin Dial 2003; 16(2): 140-7. (Pubitemid 37356826)
6. Block GA. Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens 2001; 10(6): 741-7. (Pubitemid 33043667)
7. Cannata-Andia JB, Carrera F. The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS. Nephrol Dial Transplant 2008; 1(Suppl 1): 29-35.
8. Toussaint ND, Kerr PG. Vascular calcification and arterial stiffness in chronic kidney disease: Implications and management. Nephrology 2007; 12(5): 500-9. (Pubitemid 47366641)
9. London GM, Pannier B, Marchais SJ, Guerin AP. Calcification of the Aortic Valve in the Dialyzed Patient. J Am Soc Nephrol 2000; 11(4): 778-83. (Pubitemid 30171888)
10. Petrović D, Stojimirović B. Secondary hyperparathyroidism - risk factor for development of cardiovascular complications. Med Pregl 2010; 63(9-10): 674-80. (in Serbian)
11. Petrović D, Obrenović R, Stojimirović B. Risk factors for aortic valve calcification in patients on regular hemodialysis. Int J Artif Organs 2009; 32(3): 173-9.
12. Parfrey PS. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 2000; 15(Suppl 5): 5868.
13. Petrović D, Stojimirović B. Cardiovascular morbidity and mortality in hemodialysis patients - epidemiological analysis. Vojnosanit Pregl 2008; 65(12): 893-900. (in Serbian)
14. Petrović D, Obrenović R, Trbojević-Stanković J, Majkić- Singh N, Stojimirović B. Cardiovascular mortality in hemodialysis patients: clinical and epidemiological analysis. Journal of Medical Biochemistry 2011; 30(4): 302-8.
15. Ležajić V. Serum and urinary biomarkers determination and their significance in diagnosis of kidney disease. Journal of Medical Biochemistry 2010; 29: 288-297.
16. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003; 63(85): 105-10.
17. Zoccali C, Mallamaci F, Tripepi G. Novel Cardiovascular Risk Factors in End-Stage Renal Disease. J Am Soc Nephrol 2004; 15(Suppl 1): 77-80.
18. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: An epidemiological perspective. Kidney Int 2006; 70(1): 26-33. (Pubitemid 44000117)
19. Rigatto C, Parfrey PS. Uraemic Cardiomyopathy: an Overload Cardiomyopathy. J Clin Basic Cardiol 2001; 4(2): 93-5. (Pubitemid 32822402)
20. Derić M, Čabarkapa VS. Cardiovascular biomarkers in chro nic kidney disease. Journal of Medical Biochemistry 2010; 29(4): 298-303.
21. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75(9): 890-7.
22. Chertow GM, Burke SK, Raggi P, for the Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62(1): 245-52. (Pubitemid 34754068)
23. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68(4): 1815-24. (Pubitemid 43169927)
24. Ribeiro S, Ramos A, Brandao A, Guerra A, Resina C, Vila-Lobos A, et al. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998; 13(8): 2037-40. (Pubitemid 28356772)
25. Qunibi WY. Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). Kidney Int 2004; 66(Suppl 90): 8-12.
26. Hörl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004; 19(Suppl 5): 2-8.
27. Goodman WG. The Consequences of Uncontrolled Secondary Hyperparathyroidism and Its Treatment in Chronic Kidney Disease. Semin Dial 2004; 17(3): 209-16. (Pubitemid 38824502)
28. Ventura JE, Tavella N, Romero C, Petraglia A, Baez A, Munoz L. Aortic valve calcification is an independent factor of left ventricular hypertrophy in patients on maintenance haemodialysis. Nephrol Dial Transplant 2002; 17(10): 1795-801. (Pubitemid 35174292)
29. Rufino M, Garcia S, Jimenez A, Alvarez A, Miquel R, Delgado P, et al. Heart valve calcification and calcium x phosphorus product in hemodialysis patients: Analysis of optimum values for its prevention. Kidney Int 2003; 63(Suppl 85): 115-18.
30. Zebe H. Atrial fibrilation in dialysis patients. Nephrol Dial Transplant 2000; 15(6): 765-8.
31. Aronow WS. Acute and Chronic Management of Atrial Fibrilation in Patients With Late-Stage CKD. Am J Kidney Dis 2009; 53(4): 701-10.
32. 4Product, and Parathyroid Hormone with Cardiac Mortality Risk in Chronic Hemodialysis Patients. J Am Soc Nephrol 2001; 12(12): 2131-8.
33. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality Effect of Coronary Calcification and Phosphate Binder Choice in Incident Hemodialysis Patients. Kidney Int 2007; 71(5): 438-41.
34. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis. J Am Soc Nep hrol 2004; 15(8): 2208-18. (27)
35. De Broe ME. Phosphate: despite advances in research, the benefits to patients remain limited. Kidney Int 2009; 75(9): 880-1.
36. Wolf M. Forging Forward with 10 Burning Questions on FGF in Kidney Disease. J Am Soc Nephrol 2010; 21(9): 1427-35.
37. Hutchison AJ. Oral phosphate binders. Kidney Int 2009; 75(9): 906-14.
38. Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, et al. Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium x Phosphate. Clin J Am Soc Nephrol 2006; 1(2): 305-12.
39. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Evaluation of Cinacalcet The rapy to Lower Cardiovascular Events (EVOLVE): Rationale and Design Overview. Clin J Am Soc Nephrol 2007; 2(5): 898-905.
40. Messa P, Macario F, Yaqoob M, Bouman K, Braun J, Von Albertini B, et al. The OPTIMA Study: Assessing a New Cinacalcet (Sensipar/Mimpara) Treatment Algorithm for Secondary Hyperparathyroidism. Clin J Am Soc Nep hrol 2008; 3(1): 36-45.
41. Bushinsky DA, Messa P. Efficacy of Early Treatment with Calcimimetics in Combination with Reduced Doses of Vitamin D Sterols in Dialysis Patients. NDT Plus 2008; 1(Suppl 1): 18-23.
42. Eddington H, Klara PA. The association of chronic kidney disease-mineral bone disorder and cardiovascular risk. J Ren Car 2010; 36(Suppl 1): 61-7.
43. Kanabay M, Afsar B, Goldsmith D, Covic A. Sudden Death in Hemodialysis: An Update. Blood Purif 2010; 30(2): 135-45.